Blog of Signaling Pathways

Advances in clinical studies of FLT3 inhibitors in acute myeloid leukemia

41 views | Jun 26 2023

This comprehensive review article examines the current status of FLT3 inhibitors in clinical research for acute myeloid leukemia (AML) patients and explores treatment strategies, including combination therapies, to overcome drug resistance and improve patient outcomes. [Read the Full Post]

Telomerase deficiency and dysfunctional telomeres in the lung tumor microenvironment impair tumor progression in NSCLC mouse models and patient-derived xenografts

28 views | Jun 26 2023

Targeting telomeres through TERT inhibition shows promise as a potential therapeutic strategy for reducing tumor growth and improving outcomes in non-small cell lung cancer (NSCLC). [Read the Full Post]

Results of a Phase II Trial Testing the Resensitization With Trabectedin in Platinum-resistant Ovarian Cancer

45 views | Jun 26 2023

The study found that while trabectedin did not result in widespread resensitization to platinum-based chemotherapy in heavily pretreated patients with platinum-resistant ovarian cancer, a significant proportion of patients achieved disease control with the treatment. [Read the Full Post]

Efficacy and safety of long-acting cabotegravir versus oral tenofovir disoproxil fumarate-emtricitabine as HIV pre-exposure prophylaxis: A systematic review and meta-analysis

54 views | Jun 26 2023

The study found that long-acting injectable cabotegravir (CAB-LA) was more effective than daily oral tenofovir disoproxil fumarate-emtricitabine (TDF-FTC) in preventing HIV infection among at-risk cisgender men who have sex with men (MSM) and transgender women who have sex with men. [Read the Full Post]

Intensity of endogenous thrombocytopenia after autologous stem cell transplantation in patients prophylactically transfused with platelets

26 views | Jun 26 2023

The study demonstrated that monitoring endogenous platelet counts using digital droplet PCR can accurately assess the impact of myelosuppressive chemotherapies on platelet regeneration, aiding in the development of tailored platelet transfusion regimens for patients undergoing high-dose chemotherapy with autologous stem cell transplantation. [Read the Full Post]

JMJD6 protects against isoproterenol-induced cardiac hypertrophy via inhibition of NF-κB activation by demethylating R149 of the p65 subunit

102 views | Jun 25 2023

The study demonstrates that Jumonji C domain-containing protein 6 (JMJD6) protects against pathological cardiac hypertrophy by interacting with NF-κB p65, inhibiting its nuclear translocation, and demethylating histone substrates, suggesting JMJD6 as a potential therapeutic target for cardiac hypertrophy and heart failure. [Read the Full Post]

Bridging Gaps in HDR Improvement: The Role of MAD2L2, SCAI, and SCR7

93 views | Jun 25 2023

This study demonstrated that MAD2L2 knockdown and SCR7 treatment significantly improved homology-directed repair (HDR) efficiency during CRISPR/Cas-mediated genome editing, offering valuable insights for enhancing precise correction in gene editing. [Read the Full Post]

New therapy for pancreatic cancer based on extracellular vesicles

116 views | Jun 25 2023

The study demonstrates that loading chemotherapeutic drugs into small extracellular vesicles derived from the RWP-1 cell line using the direct incubation method holds promise as an efficient drug delivery system for pancreatic ductal adenocarcinoma, with potential for further preclinical investigation and combination with a PRMT5 inhibitor in clinical trials. [Read the Full Post]

PRMT5-mediated RNF4 methylation promotes therapeutic resistance of APL cells to As2O3 by stabilizing oncoprotein PML-RARα

60 views | Jun 25 2023

The study demonstrates that PRMT5 is highly expressed in APL patients and its inhibition, either alone or in combination with As2O3, shows promising therapeutic potential by promoting the degradation of the oncogenic PML-RARα protein and inhibiting APL cell growth, differentiation, and survival. [Read the Full Post]

Modulation of blood-brain tumor barrier for delivery of magnetic hyperthermia to brain cancer

79 views | Jun 25 2023

This proposed approach utilizes a polymeric nanocarrier to deliver fingolimod and modulate the blood-brain tumor barrier, allowing for targeted accumulation of magnetic nanoclusters and synergistic magnetic hyperthermia therapy for the treatment of glioblastoma [Read the Full Post]

Therapeutic Targets in Myelodysplastic Neoplasms: Beyond Hypomethylating Agents

103 views | Jun 24 2023

This review discusses the current management strategies and promising novel targeted therapies under investigation for the treatment of high-risk myelodysplastic neoplasms (MDS), highlighting the need for alternative options due to the limitations of allogeneic hematopoietic stem cell transplantation and the challenges associated with hypomethylating agents (HMAs). [Read the Full Post]

Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study

119 views | Jun 24 2023

The combination of eprenetapopt and venetoclax with azacitidine showed promising activity and an acceptable safety profile in patients with TP53-mutated acute myeloid leukemia, supporting further evaluation of this combination as a frontline treatment option. [Read the Full Post]

Structural insights into the potency and selectivity of covalent pan-FGFR inhibitors

78 views | Jun 24 2023

This study investigates the potency, selectivity, and ability to overcome gatekeeper mutations of covalent pan-FGFR inhibitors, providing valuable insights for the development of next-generation inhibitors with improved properties. [Read the Full Post]

Expression of RNA polymerase I catalytic core is influenced by RPA12

40 views | Jun 24 2023

The study demonstrates that while RPA12 influences the basal expression and localization of the Pol I subunits RPA194 and RPA135, it does not affect their interaction or the transcriptional activity of Pol I, and the degradation of RPA194 induced by the small-molecule inhibitor BMH-21 is independent of RPA12. [Read the Full Post]

Short-term follow-up pilot study of sole middle meningeal artery embolization for chronic subdural hematoma: influence of internal architecture on the radiological outcomes

88 views | Jun 24 2023

The study found that patients with separated chronic subdural hematoma (CSDH) architecture had a lower rate of achieving the radiological endpoint and a slower rate of volume reduction compared to other CSDH types when treated with middle meningeal artery embolization (MMAE). [Read the Full Post]

Prognostic implication and immunotherapy response prediction of a ubiquitination-related gene signature in breast cancer

57 views | Jun 23 2023

[Read the Full Post]

Small molecule drugs promote repopulation of transplanted hepatocytes by stimulating cell dedifferentiation

0 views | Jun 23 2023

In summary, our findings suggest that the utilization of small molecule compounds that promote hepatocyte dedifferentiation may enhance the proliferation and efficacy of transplanted hepatocytes, offering potential advancements in hepatocyte therapy for end-stage liver disease. [Read the Full Post]

Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) trial in acquired PARP-inhibitor-resistant homologous recombination deficient ovarian cancer

102 views | Jun 23 2023

The combination of olaparib and ceralasertib shows promising activity and tolerability in patients with acquired PARPi-resistant high-grade serous ovarian cancer, suggesting the potential of ATRi to overcome PARPi resistance in this population. [Read the Full Post]

AZD8186 in Combination With Paclitaxel in Patients With Advanced Gastric Cancer: Results From a Phase Ib/II Study (KCSG ST18-20)

43 views | Jun 23 2023

[Read the Full Post]

Role of Aryl Hydrocarbon Receptor and Oxidative Stress in the Regioselective Toxicities of Hydroxychrysenes in Embryonic Japanese Medaka (Oryzias latipes)

92 views | Jun 23 2023

The study suggests that the toxicity of 2-hydroxychrysene (2-OHCHR) in embryonic Japanese medaka is mediated by aryl hydrocarbon receptor (AhR) activation, up-regulation of cytochrome P450 enzymes, and the generation of reactive oxygen species, leading to anemia and mortality. [Read the Full Post]